Updated Aug 18 at 11:16am ET.
Follow Jazz Pharmaceuticals to never miss an important update.
SEC filing on 2026-08-10: 8-K, 8-K filing: entered a material agreement.
Source: 8-K filing
Jazz is buying Actio Biosciences to get its hands on a new drug candidate for a rare, inherited type of epilepsy. This specific condition currently has no approved treatments. The deal is structured so that Jazz pays some money now and more later if the drug hits certain development goals, with the total value potentially reaching about 1.3 billion dollars.
This move fits right into the company's plan to grow its epilepsy business. Jazz already has a billion-dollar drug in this space called Epidiolex, and adding new treatments helps the company rely less on its older sleep medicines. While the drug is still in the testing phase and carries the usual risks of clinical trials, it targets a market with no competition, which could make it a valuable addition if it reaches patients.
Source: Reuters
Morgan Stanley increased its price target from $245 to $280 while keeping an Overweight rating, which is their way of saying they expect the stock to perform better than others in its sector. This roughly 14 percent increase reflects confidence in the company's ability to grow its newer drug portfolio.
While the stock is already up significantly this year, this move suggests analysts see more room for growth as the company shifts away from older medicines that face competition from cheaper generic versions.
Source: Morgan Stanley
The company reported quarterly revenue of about 1.21 billion dollars, which was higher than the 1.11 billion dollars analysts expected. While earnings per share of $5.71 came in below the $6.18 estimate, the underlying business showed strength where it matters most for long-term owners. Sales of Xywav, the newer version of its narcolepsy drug, grew 13 percent, and its epilepsy treatment Epidiolex grew 16 percent.
This growth is vital because it proves the company is successfully moving patients to newer, patent-protected medicines before its older products face competition from cheaper generic alternatives. Management felt confident enough in this momentum to raise its sales forecast for the full year. They are also preparing to launch a new cancer drug, Ziihera, which could provide another source of revenue soon.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
The U.S. government announced that imported generic drugs will not face new taxes, known as tariffs, for at least two more years. For a company like this, the news is a double-edged sword. While it keeps costs lower for some parts of the industry, it also ensures that cheaper generic versions of its older, off-patent drugs can continue to enter the market easily.
This decision makes the company's current strategy even more important. It is working to move its customers toward newer, low-sodium versions of its treatments that are protected by patents and cannot be easily copied by generic rivals. As long as that transition continues to go well, the lack of tariffs on older generic drugs should not hurt the business's long-term value.
Analysts issued a flurry of price target increases following the company's second-quarter earnings report. Most analysts, 43 of 48, rate the stock a buy, with an average target price of $282 that suggests 11% upside from current levels.
The company has a habit of growing its sales by double digits, though its actual profit numbers can be jumpy from quarter to quarter.
| Expectation | |
|---|---|
| EPS | $6.49 |
| Revenue | $1.21B |
Seeking Alpha · Opinion · Aug 12
CNBC · Aug 11
Reuters · Aug 10
PRNewsWire · Press release · Aug 10
Seeking Alpha · Opinion · Aug 5
PRNewsWire · Press release · Aug 3
Follow Jazz Pharmaceuticals to get the latest and most important updates.
Follow JAZZ